Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms with an annual incidence of 4.1 cases per 100,000 Americans. Patients with MDS suffer from chronic cytopenias that may lead to recurrent transfusions, infections, and increased risk for bleeding. They are also at risk for progression to acute myeloid leukemia. Allogeneic hematopoietic cell transplantation is the only potentially curative treatment for MDS, although 3 drugs have been approved by the US Food and Drug Administration for its treatment: lenalidomide, 5-azacitidine, and decitabine. These therapies can be effective in the relief of cytopenias, achievement of cytogenetic remissions, and reduction in bone marrow blasts. 5-azacitidine has also been shown to improve overall survival. However, there remain many unmet needs in the treatment of MDS. Breakthroughs in our understanding of the complex pathogenesis of MDS through epigenetic, genetic, immunologic, and other biological mechanisms have allowed us to develop new therapeutic strategies that can lead to improvements in outcomes in MDS. In this review, we aim to provide an overview of the evolution in classifcation and risk stratifcation in MDS and to illustrate how we can use this to guide us in tailoring therapeutic choices in this disease. Responses and outcomes related to commonly used MDS therapies will be discussed together with novel therapies that have evolved with the improved understanding of MDS pathophysiology.
M yelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell neoplasms that are characterized by aberrant myeloid lineage diferentiation, dysplastic myeloid changes, inefective hematopoiesis, and increased genomic instability. Tis is manifested clinically by chronic peripheral blood (PB) cytopenia(s) and an increased risk of progression to acute myeloid leukemia (AML). 1 MDS is not only genetically and morphologically heterogeneous but also can vary signifcantly in its natural history and prognosis. Some MDS patients have symptomatic disease with survival limited to a few months, whereas others are only minimally symptomatic with survival measured in decades. 2 MDS is predominantly a disease of the elderly. About 86% of patients with MDS are diagnosed after the age of 60 years, with a median age at diagnosis of 76 years. MDS infrequently occurs in patients aged 50 years or younger, accounting for only 6% of cases. 3 Men have a higher incidence rate of MDS than do women, and whites have higher incidence rates than do other ethnic groups. 3 Tere was a steady increase in the age-adjusted incidence rate of MDS in the United States during [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] . Tere were 3.6 cases per 100,000 people in 2001, 3.8 cases in 2002, and 4.1 to 4.6 cases per 100,000 persons from 2003 to 2008. 2 Tat corresponds to about 15,000-20,000 new cases per year in the United States. As the incidence of MDS is slightly higher than that of AML and survival rates in patients with MDS are considerably higher compared with patients with AML, the prevalence of MDS is far greater than that of AML. Despite this growing prevalence, MDS remains understudied compared with many other hematologic malignancies. Although most MDS cases are de novo, about 10% of MDS patients have secondary or therapyrelated MDS. 2 Prognosis in secondary MDS is poorer compared with that in de novo MDS, with more complex cytogenetic abnormalities, and it is expected that rates of secondary MDS will continue to rise with increased use of chemotherapy and radiation for other primary malignancies.
defect may be the cause behind chromosomal instability and repetitive chromosomal defects in MDS. 5, 6 More than 40 recurrently mutated genes have been identifed in patients with MDS, with several more being discovered as genome sequencing technologies continue to improve. A recent large study demonstrated that 78% of MDS cases had at least 1 or more of these recurring mutations, which are summarized by the genetic pathways in Table 1 . 7 Mutations of splicing factors genes (SF3B1, SRSF2, U2AF1, and ZRSR2), for example, are present in 12.4% of MDS patients and have been shown to carry prognostic signifcance. 8 Mutations in SF3B1 play a role in the pathogenesis of the MDS subtype refractory anemia with ringed sideroblasts (RARS), with those patients having a more favorable prognosis than those with the wild type gene. [9] [10] [11] It is likely that every MDS patient harbors 1 or more somatic driver mutation responsible for the development and progression of the disease. Te diverse manner by which these driver mutations coexist can help explain the clinical variability associated with MDS and can therefore aid in disease classifcation and outcome prediction. 12 Tese genetic abnormalities are among the strongest prognostic indicators and can also afect therapeutic decision. Clonal karyotypic abnormalities, which are detected using conventional karyotyping, are observed in 50% of patients with MDS. Te most common chromosomal aberrations in MDS include deletions of the long arm of chromosome 5 (del5q), monosomy Y, monosomy 7 (7q-); or deletion of its long arm (del7q), trisomy 8, del20q, and complex karyotypes (≥ 3 chromosomal aberrations). Tese chromosomal changes can be identifed through various methods, including metaphase cytogenetics, fuorescence in situ hybridization, or single nucleotide polymorphism array analysis. Tese cytogenetic abnormalities correlate with the prognosis of patients with MDS (eg, poor prognosis with complex karyotypes and 7q-compared with better prognosis with isolated del5q). 4, [13] [14] [15] Immunologic aberrations have also been proposed to contribute to the pathogenesis of MDS. For example, in early-stage MDS, an aberrant immune attack on myeloid progenitors resulting in increased apoptosis can contribute to bone marrow (BM) failure. Tis is supported by the association of some forms of MDS with autoimmune diseases and observed responses in some patients to immunosuppressive therapies. 16 Tumor necrosis factor-alpha (TNF-α) is a well-recognized cytokine that has been found to promote apoptosis in erythroid cells in the early stages of MDS. Indeed, the inefective hematopoiesis present in MDS seems to be the result of excessive apoptosis of hematopoietic precursors, which explains the apparent paradox of a hypercellular BM and PB cytopenias. 17 In addition to intrinsic sensitivity to apoptosis induction, the stromal microenvironment has been shown to impair the ability to support diferentiation. 18 Other recently elucidated path- www.jcso-online.com Review ways that are important in MDS pathogenesis include MAP kinase, aberrations in P38 pathway, and tumor growth factor-beta (TGF-β) pathway.
Prognostic classifcation
Because of the heterogeneity in the morphology as well as outcomes of MDS, attempts at classifying it into subtypes that have common morphology, molecular causes, responses to treatment, and prognosis began only in the 1980s. Te French-American-British (FAB) system, introduced in 1976, was the frst classifcation scheme for MDS. Tis scheme is primarily based on morphology, BM and PB blast percentage, and PB monocyte count. 19, 20 Te FAB classifcation designates 5 categories: refractory anemia (RA), RARS, RA with excess blasts (RAEB), chronic myelomonocytic leukemia (CMML), and RAEB in transformation (RAEB-T). Although the FAB system is a diagnostic classifcation, it also has major prognostic relevance. 21, 22 Te International Prognostic Scoring System (IPSS) followed the FAB and it is the result of combined cytogenetic, morphologic, and clinical data from 7 large riskbased MDS studies. Since its inception in 1997, it has formed the foundation for clinical and therapeutic guidelines and has become the standard clinical tool for risk assessment in patients with MDS. 23 Te IPSS classifes de novo MDS patients into 4 groups: low risk, intermediate-1
, and high risk, based on BM blast proportion, cytogenetics, and PB cytopenias. Te corresponding median overall survival (OS) of these groups is 5.7, 3.5, 1.2, and 0.4 years, respectively. 23 Despite its success as a prognostic scoring system, several limitations of the IPSS became evident over time. Tis includes its exclusion and thus inapplicability to therapy-related (t)-MDS, proliferative CMML patients with white blood cell count of > 12,000/uL) and MDS/myeloproliferative neoplasms (MPN) overlap phenotypes. Te original IPSS also did not account for important prognostic parameters such as red blood cell (RBC) transfusion-dependence, severity of cytopenias, and multilineage dysplasia, and underweighted the prognostic importance of karyotype relative to BM blasts. 24, 25 It also included patients with up to 30% of blasts in their BM (considered to have AML by current World Health Organization [WHO] criteria), and it has been demonstrated that the original IPSS underestimated the poor outcome of a signifcant subgroup of patients classifed by the IPSS as low or INT-1 who actually had an aggressive disease course with shorter survival than predicted by the IPSS. 26, 27 To overcome those limitations of the IPSS, a much larger cohort of patients (n = 7,012, compared with the original IPSS cohort of n = 816) was used to update and create what is now called the Revised IPSS (R-IPSS).
Compared with the IPSS, the R-IPSS incorporates more chromosomal abnormalities and cytogenetic risk groups, gives more weight to the severity of individual cytopenia(s), decreases the relative weight of BM blasts, and stratifes patients based on these criteria into 5 prognostic groups (very low, low, intermediate, high, and very high) with signifcantly diferent outcomes instead of the 4 groups in the IPSS. 28 Although the R-IPSS better defnes the risk stratifcation and the prognosis of MDS patients, it still does not incorporate any of the epigenetic, genetic, and immunologic prognostic markers; and as with the IPSS, it does not address t-MDS and MDS-MPN overlap patients. Furthermore, the multiplicity of factors included and the new cytogenetic categorization makes the assessment cumbersome and difcult to use in its complexity in a typical community setting.
Both the IPSS and R-IPSS were designed for patients at time of a new diagnosis of MDS and may not be as applicable to a patient who has been previously diagnosed or is already undergoing treatment with diseasemodifying agents. However, the Groupe Francophone des Myelodysplasies used the R-IPSS in 282 INT-2 to highrisk MDS patients treated with AZA and found that it may provide prognostic value for survival. Using timedependent covariates, the World Prognostic Scoring System was developed as a dynamic scoring system that can be used at any time during a patient's disease course and takes into account factors such as WHO diagnosis, cytogenetic risk grouping using the original IPSS cytogenetic risk categorization, and RBC transfusion dependence. 29 To overcome the limitations of IPSS, other prognostic scoring systems have been developed. Tese include the MD Anderson Comprehensive Scoring System (MDACSS), which used data from 1,915 patients. Tis prognostic model gives weight to age, performance status, and severity of cytopenias. It divides MDS patients into 4 risk groups with distinct diferences in survivals. Te major advantage of the MDACSS is that it includes patients with CMML, MDS-MPN overlap, and t-MDS; and it is dynamic in nature and therefore can be used for previously diagnosed patients who are seen in the clinic. A disadvantage to this prognostic system is its complexity, which has limited its clinical usage despite its diagnostic precision. Table 2 summarizes the prognostication systems.
Although these prognostic tools were developed to inform clinical decision-making, it is important to remember that none was designed to predict the patient's response to any particular therapeutic modality for MDS.
Management of patients with MDS
Despite the recent advances in MDS drugs, allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potential curative treatment for MDS and other myeloid neoplasms. As such, it should always be considered as a potential therapeutic option, especially in higher-risk MDS. However, fewer than 5% of MDS patients can beneft from allo-HCT because of their advanced age, associated comorbidities, and/or lack of suitable donors. 30 After it has been determined that the patient is not a candidate for transplant, the next step in management is to decide whether to use disease modifying agents that can alter the disease course or supportive therapies that include expectant management, RBC and platelets transfusion, hematopoietic growth factors, antibiotics, and iron chelation agents when needed. Tree disease-modifying agents have 
Lower-risk MDS
Patients in this group are either asymptomatic or have symptoms related to peripheral cytopenias and mostly related to anemia, such as persistent fatigue and dyspnea on exertion. Asymptomatic patients may only need periodic PB count monitoring. In symptomatic LR-MDS patients, the goal of therapy is to minimize the need for blood transfusions, alleviate symptoms, and improve their quality of life. Te 3 most commonly used drugs for the treatment of these groups of patients are erythropoiesis-stimulating agents (ESAs), immune suppressive therapy (IST), and lenalidomide ( Figure 1 ). Supportive management through careful blood count monitoring and judicious use of transfusion of blood components, antibiotics, and iron chelation may also be appropriate for some LR-MDS.
ESAs -epoetin, darbepoetin. Anemia is the most commonly encountered cytopenia in MDS patients. About 80%-90% of MDS patients develop anemia during the course of the disease and of those, 40% become transfusion dependent. 29, 31 Anemia in MDS is the result not only of inefective erythropoiesis but also the lack of response to erythropoietin. ESAs are the most commonly used therapy for MDS even though they have not been approved by the FDA for the treatment of MDS-related anemia. 32, 33 Before starting treatment with an ESA, it is important to correct any contributing factor to anemia, such as nutritional defciencies (iron and folate) and gastrointestinal (GI) bleeding. 30 Te doses of ESAs used for MDS-related anemia, a condition associated with relative intrinsic resistance to erythropoietin, are higher than those used for renal disease-related anemia, which is usually associated with normal BM responsiveness. According to the National Comprehensive Cancer Network management guidelines for myelodysplastic syndromes, the recommended starting doses are 40,000-60,000 units given 1-3 times a week for the recombinant human erythropoietin alpha (rEPO) and 150-300 mcg/week for the longer-acting form of darbepoetin, with both agents administered subcutaneously. Darbepoetin, administered every 3 weeks at a dose of 500 mcg also seems efective in correcting anemia associated with LR-MDS. 34, 35 A minimum of 6-8 weeks of ESA treatment is recommended to evaluate ESA response before deciding to discontinue therapy.
ESAs in MDS have been associated with increased risk of thromboembolic events compared with ESAs in certain solid tumors. 36 About 40% of LR-MDS patients treated with ESAs achieve signifcant erythroid response with median response duration of 2 years, without an increased risk of leukemia progression. 37, 38 Based on a meta-analysis of 162 MDS trials conducted during 1985-2005, ESAs have been shown to provide an OS beneft and to decrease the rate of disease progression compared with non-ESA therapies. However, this has not been proven in any prospective, randomized clinical trial. Granulocyte colony stimulating factors can be synergistic with ESAs to augment erythroid response rate especially in patients with RARS. 33 In LR-MDS transfusion depended patients who failed ESA treatment, lenalidomide should be taken into consideration even without (5q-) syndrome.
Lenalidomide. Te (5q-) syndrome is a subgroup of MDS characterized by deletion of the long arm of chromosome 5. Patients with this syndrome usually have refractory macrocytic anemia, normal or increased platelet count, low BM blast percentage, and small hypolobated dysplastic megakaryocytes. Tey also have an indolent course and lower rates of leukemic progression. 39, 40 Lenalidomide, an orally bioavailable derivative of thalidomide, is an immunomodulatory agent that can lead to high response rates in LR-MDS patients with 5q deletion. In a phase 2 trial, transfusion independence (TI) was achieved in 67% of patients, with a median response rate of more than 2 years. In addition, complete cytogenetic response was observed in 45% of patients and partial cytogenetic response was observed in 73% of patients, indicating a direct cytotoxic efect of lenalidomide on the neoplastic clone. Tere was also signifcant improvement in quality of life and reduction in leukemic progression noted in patients who responded to lenalidomide therapy. 40, 41 On the basis of those fndings, lenalidomide was approved by the FDA for the treatment of LR-MDS (IPSS low or INT-1) patients with (5q) deletion. Despite the encouraging results of lenalidomide in this group of patients, no prospective study has shown a survival beneft with long-term usage. 41 Lenalidomide also has efcacy in non-del5q patients. TI was achieved in 26% of non-del5q patients after a median of 4.8 weeks of treatment and responses were generally robust with a median duration of response of 41 weeks.
In higher-risk MDS (HR-MDS) patients with (5q) deletion, TI was achieved in 25% of the patients with a median duration of TI of 6.5 months. 43 Side efects observed with lenalidomide therapy include: skin rash, dryness and pruritus, fatigue and muscle cramps, nausea and GI disturbance, appearance of new cytopenia(s) especially neutropenia and thrombocytopenia, or worsening of existing cytopenia(s) and associated complications (bleeding, fatigue, and infection).
Immunosuppressive therapy. Multiple prospective studies have been conducted to assess response to IST as a therapeutic intervention for MDS. In a large analysis of 139 MDS patients who received IST cyclosporine A (CSA), antithymocyte globulin (ATG), or both, the median follow-up was 3 years. Te overall response rate (ORR) was 30% (8% for CSA, 24% for ATG, 48% for combination). 44 Hematologic response to IST is usually slow and may require up to 6 months to fully manifest. Several factors have been associated with higher hematologic response to IST in patients with MDS, including patients with younger age (< 60 years), female gender, LR-MDS, BM hypocellularity, normal karyotype, HLA-DR 15 histocompatibility type, trisomy 8, and presence of a paroxysmal nocturnal hemoglobinuria clone. Based on these favorable characteristics, a scoring system to identify patients who will best respond to IST therapy has been developed. 34, 44 Patients with IPSS-LR who fail therapy and those with severe thrombocytopenia or severe neutropenia can be considered for hypomethylating agent (HMA) therapy and allo-HCT if eligible. 45 
Higher-risk MDS
Patients with HR-MDS have very poor prognosis, with a survival of less than 1 year if they are not treated. 23 In appropriate candidates, allo-HCT can cure up to 40% of MDS patients; therefore eligibility for transplant should be evaluated in all HR-MDS patients. 46 Te goal of treatment in patients who are not eligible for transplant is to modify the natural course of the disease and to prolong survival using HMAs and in some cases, high-intensity chemotherapy (Figure 2 ).
Hypomethylating agents. HR-MDS are associated with a higher number of methylated gene loci in the promoterassociated CpG islands. Te increased number of methylated loci is associated with disease progression from LR-MDS to HR-MDS. 47 HMAs (azacitidine [AZA] and decitabine [DAC] ) are inhibitors of DNA methyltransferases, which are the enzymes responsible for cytosine methylation. 48 HMA therapy has been approved by the FDA for all subtypes of MDS patients. In clinical practice, it is usually used in patients with an initial diagnosis of HR-MDS and in LR-MDS patients who have failed previous and other treatments.
Te approved regimens of HMAs in the treatment of MDS result in an ORR of 40%-60 % and a complete remission (CR) of 10%-20%, with a median CR duration of 12-14 months and a partial remission (PR) of 10-20 months. [49] [50] [51] Te regimens also improve the quality of life in MDS patients and delay progression to leukemia. Both of the drugs can lead to improvements in blood counts and a reduction of transfusion needs. [49] [50] [51] However, only AZA has also been shown to prolong median OS in HR-MDS patients in a phase 3 study. 50 Terapy with an HMA is not curative and patients are maintained on treatment as long as they are responding and not experiencing major side efects. Eventually, however, all patients will lose response to HMAs. In the frst randomized phase 3 trial on AZA, it was compared with best supportive care in patients with MDS of all subtypes. Although AZA showed beneft in terms of survival and delay in AML transformation, it didn't signifcantly prolong survival as an endpoint because the study allowed crossover between AZA and supportive care arms. 51 Subsequently, a large phase 3 study was conducted on 358 patients with HR-MDS; patients were randomized to receive either AZA or best conventional care regimen (best supportive care, low-dose cytarabine, or induction chemotherapy) without crossover. Patients in the AZA group received 75 mg/m 2 daily doses for 7 consecutive days of a 28-day cycle with a median of 9 treatment cycles. Results from the study showed a 9% ORR with AZA, compared with 21% in the conventional care arm. More important, however, the median OS was signifcantly prolonged in the AZA arm (25 months) compared with the conventional-care arm (15 months), which resulted in a survival advantage of 9.5 months. 50 Te median number of cycles to achieve a response is 3, and at least 4-6 cycles of AZA may be needed to achieve the best clinical response. 52 Further improvement may occur with continued treatment and is recommended as long as the patient maintains response and has no major side efects. 53 In clinical practice, outpatient administration of AZA daily for 7 consecutive days is often not feasible because of the limitations of available ofce hours. To address this issue, other AZA dosing schedules have been evaluated and found to result in similar responses. However, it remains unclear if these alternative dosing schedules have the same survival beneft.
54 Decitabine (DAC) is another HMA with FDA approval at a dose of 15 mg/m 2 every 8 hours over 3 days, repeated every 6 weeks, and 20 mg/m 2 over 1 hour intravenously (IV) daily for 5 days of a 28-day cycle. 55, 49 DAC was compared with best supportive care in 2 randomized, phase 3 studies. One was conducted in patients with mixed MDS risk groups 49 and the other was conducted in Europe on HR-MDS only. 56 None of these studies has shown a sig-www.jcso-online.com
Review nifcant survival advantage. Patients who do not respond to HMA therapy and progress to AML have very poor outcomes, with a median OS of less than 6 months. 57 Te most common side efect of HMA therapy is myelosuppression. Tere is controversy over whether dose reduction, delaying a cycle, or maintaining the same dosing is indicated in this case. 58, 59 Ways to obviate this include dose adjustment and judicious use of growth factors. Other less common side efects are fatigue, gastrointestinal disturbance, and local reactions to subcutaneous injection (SQ). IV administration of AZA (same dose/schedule) is a reasonable alternative in cases of signifcant local reactions to the SQ formulation or limited SQ tissue owing to cachexia.
58, 60
High-intensity chemotherapy. Te use of intensive induction chemotherapy regimens similar to those used in AML results in modest clinical responses and signifcant toxicity, especially in elderly patients, who comprise the majority of MDS patients. Te CR rate associated with intensive chemotherapy of MDS is lower compared with patients with de novo AML (40%-60%) and usually lasts for less than a year. Tere are some studies that show that the outcome of patients who receive intensive chemotherapy for treatment of AML arising from MDS is worse compared with de novo AML patients. 49, 61 Terefore, given the high toxicity associated with chemotherapy and the absence of superior outcomes compared with HMA therapy, the use of intensive chemotherapy in MDS is usually restricted to younger patients with good performance status requiring cytoreduction before allo-HCT.
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Novel therapies
Treatment for MDS remains an unmet medical need, and allo-HCT is the only curative option for MDS. Te increasing knowledge about the complex pathogenesis of MDS, the key genetic alterations that drive progression, and the mechanisms of action and resistance to current therapies will be vital for the development of novel and targeted treatments.
Histone deacetylase inhibitors -vorinostat, panobinostat, entinostat, and belinostat. Drugs that inhibit a group of enzymes called histone deacetylases (HDACs) that are important in posttranslational histone modifcation and exert epigenetic control over gene expression have been tested in MDS. Inhibition of HDACs pharmacologically may result in cell cycle arrest and subsequent apoptosis. 48 Although histone deacetylase inhibitors (HDACIs) have demonstrated very modest singleagent activity in MDS and AML clinical trials, synergistic antileukemic activity can be achieved in vitro by combining HMA therapy and HDACIs. 63 HDACIs can also be used with AZA in combination strategies (see Combination strategies). P38-MAPK inhibitor. Te accelerated apoptosis seen in LR-MDS is a result of intrinsic clone susceptibility and pro-infammatory cytokines that suppress the normal and MDS clone. Te P38 mitogen-activated protein kinase (MAPK) pathway is a divergent pathway for several infammatory signals. It is overactivated in LR-MDS. 64 SCIO-469 (a P38-MAPK inhibitor) was tested in 62 patients with LR-MDS in a phase 1/2 clinical study. Hematological improvement (HI) was reported in 29% of patients (18% erythroid response, 12% platelet response, and 25% neutrophil response). 65 Arry-614 is a potent dual inhibitor of P38-MAPK and of Tie 2 (angiopoietin receptor). In a phase 1 multicenter study, single daily dose was escalated to 1,200 mg orally daily with no maximum tolerated dose (MTD) reached. Te twice-a-day dose cohort was discontinued given dose-limiting toxicities at 300 mg twice daily level. Te most common side efects were rash and diarrhea. Overall, HI was 30% (erythroid 20%, platelets 32%, and neutrophils 31%). Te response rate was higher at the 1,200 mg dose (38%) and 67% had a bilineage response.
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Transforming growth factor beta -LY2157299, sotatercept.
Myelosuppressive cytokines such as TGF-β are important regulators of hematopoiesis. Te levels of TGF-β were found to be increased in the plasma and BM progenitors of patients with MDS, and its constitutive activation leads to inefective hematopoiesis in LR-MDS. 67 Sotatercept is a chimeric protein composed of the Fc portion of the IgG receptor fused to the Activin receptor 2 protein. Inhibition of TGF receptor I leads to increased hematopoietic colony formation from primary MDS hematopoietic progenitors in vitro.
Indolemine 2, 3 dioxygenase 1 inhibitor. IDO1 is a ratelimiting enzyme in the catabolic pathways of tryptophan. It is overactivated in diferent cancers and blocks tumor specifc cytotoxic T-cell activity, which is a key element for the induction of tumor immune tolerance. IDO1 inhibition increases T-cell proliferation and decreases regulatory T cells. 68 INCB024360 is a novel, potent, and selective inhibitor of the enzyme IDO1 that will be tested in a phase 2 study in patients with MDS.
Aminopeptidase inhibitor -tosedostat. Inhibition of the aminopeptidase enzyme depletes intracellular amino acid pools that are crucial for tumor cell survival. Tosedostat, an oral inhibitor of aminopeptidase, was tested in phase 1 and phase 2 studies in MDS-AML and was well tolerated. Trombocytopenia was the most common toxicity observed.
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Hedgehog inhibitors. Te Hedgehog pathway is active in many hematologic malignancies and seems to be responsible for drug resistance. 70 Inhibition of this pathway may hold promise for overcoming drug resistance and to possibly achieve cure or long-term control of MDS. An example of this approach is the use of the smoothened inhibitor PF-04449913, which interferes with the sonic hedgehog self-renewal pathway in stem cells. A frst in-human phase 1 study of PF-04449913 in patients with AML, primary myelofbrosis, chronic myelogenous leukemia, and MDS demonstrated efcacy in all 4 diseases. One of the 3 patients with LR-MDS achieved a reduction in spleen size and an HI in platelets and neutrophils. Of the 18 patients with AML, 1 had a decrease in BM blasts, from 92% to 1%, without HI. Another 5 patients had at least a 50% reduction in the BM blasts. Constitutional symptoms and splenomegaly are generally not an issue in primary MDS compared with MF, although they can be seen in MDS-MPN overlap syndrome, such as CMML. 75 An ongoing clinical trial is evaluating the efcacy of ruxolitinib in CMML. Momelotinib is a selective JAK inhibitor, which in early studies has shown to have additional efcacy in potentially improving anemia. Although the mechanism for anemia response remains unclear, if confrmed, momelotinib may be a useful therapeutic option for patients with MDS.
Glutathione S-transferase 1-1 inhibitor. Ezatiostat is a glutathione S-transferase 1-1 inhibitor that shares structural homology with native glutathione and can thus displace it from its binding site, which is needed to inhibit the Jun kinase pathways. Tis leads to the activation of proapoptotic Jun kinase proteins in cancer cells that express glutathione S-transferase pi-1 (GSTP1-1). Ezatiostat promotes growth and maturation of normal hematopoietic progenitors and induces apoptosis in cancer cell lines. 76 A recent phase 2 trial of ezatiostat using 2 dosing schedules for low-/INT-1-risk MDS (n = 89) led to RBC transfusion reduction in 29% of patients and independence in 11%. Recently, a nuclear transcription factor has been discovered in many myeloid malignancies called ecotropic viral integration site 1. EVI-1 genetic translocation leads to activation of this factor and results in increased activity of the mTOR pathway, leading to decreased diferentiation and increased proliferation of blood cells. 80 mTOR inhibitors are currently being studied as an alternative therapeutic approach in the treatment of myeloid malignancies, including MDS.
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Combination strategies
Except for allo-HCT, AZA is the only drug that has been shown prospectively to prolong survival in patients with MDS. However, AZA monotherapy is efective in only half of the patients, with a modest CR rate of 10%-20%. Furthermore, treatment with AZA is noncurative, and patients eventually lose their response to therapy usually after 2 years of treatment. 82 Patients with MDS who develop primary or secondary resistance to HMAs have dismal prognosis with a reported median OS of less than 6 months. 57 Terefore, novel therapeutic approaches are desperately needed. Given the proven survival advantage of AZA, HMA-based platforms represent an appealing combination approach. Te goal of these combination strategies is to increase and prolong the response rate to AZA and ultimately prolong survival compared with AZA monotherapy.
In a phase 2 study in patients with HR-MDS, encouraging results were observed when AZA (75 mg/m 2 day 1 through 5 every 28 days) was combined with lenalidomide (10 mg daily day 1 through 21). Of 36 patients with HR-MDS in a phase 2 study, the ORR was 72% (modifed international working group criteria) and 44% achieved CR. Twenty-two percent of the patients sufered febrile neutropenia. 83 Early-phase trials that evaluated the combination of valproic acid or sodium phenylbutyrate, both older HDACIs, with AZA or DAC showed that the combinations were safe and associated with modest clinical activity. 84 Several newer HDACIs (eg, entinostat, belinostat, vorinostat, panobinostat) have been evaluated in early-phase trials in combination with HMAs. Pracinostat was combined with AZA in a phase 2 study, and the combination resulted in a CR-CRi rate of 78% (7 of 9 patients). 85 A randomized phase 2 study of 150 patients that compared AZA monotherapy with AZA plus vorinostat did not fnd a signifcant diference in median OS between the 2 groups after a median follow-up of 17 months (18 months in the monotherapy arm vs 13 months in the combination arm; P = .15) 86 Combination therapies have also been evaluated to improve erythroid responses in patients with LR-MDS. A trial evaluating the use of a combination regimen of lenalidomide and rEPO in transfusion-dependent LR-MDS patients who didn't respond to either of the agents alone showed some activity. In the frst stage of the trial, patients were treated with lenalidomide monotherapy (10 or 15 mg daily) for 16 weeks. Erythroid nonresponders received the combination regimen using rEPO at 40,000 U per week. In the frst stage with lenalidomide monotherapy, 6 of 7 patients (86%) with 5q LR-MDS and 8 of 32 patients (25%) with non-5q LR-MDS (17.7% for the 10-mg dose; 33.3% for the 15-mg dose) achieved HI-E. Twenty-three patients received the combination therapy, and 6 of them (26%) achieved HI-E, including 4 of 19 patients (21.1%) with non-5q. Tese encouraging results led to a randomized phase 3 trial to evaluate the benefts of lenalidomide plus rEPO therapy.
Conclusion
MDS is a heterogeneous hematologic disease both clinically and pathophysiologically. Advances in our current understanding of disease biology through the identifcation of various genetic mutations, epigenetic mechanisms, and immune regulatory pathways have allowed us to gain better understanding of disease complexity and clinical variability. Te identifcation of a myriad of genetic mutations has led to changes in the way we understand this disease. In terms of diagnosis, new genetic mutations have served as clonal markers for disease, which in certain circumstances have led to successful disease diagnosis in otherwise unclear diagnostic cases of MDS. For example, SF3B1 mutations can distinguish nonclonal cases of sideroblastic anemias from cases of RARS and RARS-T. In terms of prognosis, new molecular mutations can lead to better disease risk stratifcation and are fnding their way in new disease risk stratifcation schemes. New data has also shown that these genetic mutations may be predictive of therapeutic response. 87 Lastly, these new genetic markers ofer the possibility for new therapeutic targets in MDS, which can improve patient outcomes.
